Keywords: BTG, Wellstat, Uridine, 5-FU overexposure antidote

BTG acquires US rights to Wellstat’s investigational drug uridine triacetate

Article | 06 July 2011

Print This

UK specialist health care company BTG (LSE: BGC) has acquired US commercial rights to US privately-held Wellstat Therapeutics’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in